Effect of hyperhomocysteinemia and methylenetetrahydrofolate reductase 677C→T mutation in venous thromboembolism risk of young adults;Efecto de la hiperhomocisteinemia y de la mutación metilentetrahidrofolato reductasa 677C→T en el riesgo de tromboembolia venosa en adultos jóvenes

Medicina Clinica

Volumn 124, Issue 14, 2005, Pages 532-534

  Fernández Miranda, Consuelo ^a   Coto, Ángel ^a   Martínez, Joaquín ^a   Gómez, Pilar ^a   De La Cámara, Agustín Gómez ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Homocysteine; Hyperhomocysteinemia; Methylenetetrahydrofolate reductase; Thrombogenic factors; Venous thromboembolism; Young adults

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ACTIVATED PROTEIN C; ANTITHROMBIN; BLOOD CLOTTING FACTOR 5 LEIDEN; HOMOCYSTEINE; PROTEIN C; PROTEIN S; PROTHROMBIN;

ADULT; AGE; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; INFERIOR CAVA VEIN; LEG THROMBOSIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MESENTERIC VEIN THROMBOSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PORTAL VEIN THROMBOSIS; RETINA VEIN; RISK FACTOR; SPAIN; THROMBOGENESIS; VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM;

EID: 18844438693     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1157/13073939     Document Type: Article

References (10)

1. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ. 2002;325:1202-6.
2. Falcón CR, Cattaneo M, Panzeri D, Martinelli I, Mannucci PM. High prevalence of hyperhomocyst(e)inemia in patients with juvenile venous thrombosis. Arterioscl Thromb. 1994;14:1080-3.
3. Gonzalez Y, Souto JC, Mateo J, Córdoba A, Blanco-Vaca F, Fontcuberta J. Moderate hyperhomocysteinemia is a highly prevalent defect in Spanish patients with venous thromboembolic disease. Haematologica. 1998;83:1126-7.
4. Frederiksen J, Juul K, Grande P, Jensen GB, Schoeder TV, Tybjaerg-Hansen A, et al. Methylenetetrahydrofolate reductase polymorphism (C677T), hyperhomocysteinemia, and risk of ischemic cardiovascular disease and venous thromboembolism. Blood. 2004;104:3046-51.
5. Fermo I, D'Angelo S, Paroni S, Mazzola G, Calori G, D'Angelo A. Prevalence of moderate hyperhomocysteinemia in patients with early-onset venous and arterial occlusive disease. Ann Intern Med. 1995;123:747-53.
6. Brattström L, Wilcken DEL. Homocysteine and cardiovascular disease: cause or effect? Am J Clin Nutr. 2000;72:315-23.
7. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Mattews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet. 1995;10:111-3.
8. Vargas M, Soto I, Pinto CR, Urgelles MF, Coto E. Mild hyperhomocysteinemia and MTHFR C677T do not increase the risk for venous thrombosis in a Spanish population. Blood Coagul Fibrinol. 1998;9:555-6.
9. Martinez-Frías ML, Bermejo E, Rodríguez-Pinilla E, Scala I, Andria G, Botto L, et al. Frecuencia de la mutación 677C-T del gen de la metilente-trahidrofolato reductasa en una muestra de 652 recién nacidos de toda España. Med Clin (Barc). 2004;122:361-4.
10. Den Heijer M. VITRO: the vitamins and thrombosis trial. XIX Congress of the International Society of Thrombosis and Hemostasis [en línea]. 12-18 de julio de 2003. [citado 9 Ago 2004].